Promotion of Coronary Collateral Function by Ivabradine-Induced Bradycardia in Patients With Coronary Artery Disease

• Status: Completed
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study in patients with chronic stable coronary artery disease treatable by percutaneous coronary intervention (PCI) is to evaluate the long-term efficacy and safety of the orally taken selective I(f)-inhibitor Ivabradine (Procoralan®, Servier Switzerland) with regard to the promotion of collateral growth.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Inselspital, Berne

Criteria

Inclusion Criteria:

1. Age > 18 years old

2. 1- to 3-vessel stable coronary artery disease (CAD)

3. At least 1 stenotic lesion suitable for PCI

4. No Q-wave myocardial infarction in the area undergoing CFI measurement

5. Written informed consent to participate in the study

Exclusion Criteria:

1. Acute coronary syndrome

2. CAD treated best by surgical coronary bypass

3. Indications for BB treatment (heart failure, arrhythmias, <3months post-infarct)

4. RHR <60/min without any treatment

5. Sick sinus syndrome, sinuatrial block or >2nd degree atrio-ventricular block

6. Atrial fibrillation

7. Inherited or acquired long-QT syndrome

8. Indwelling pacemaker

9. Severe hepatic or renal failure (creatinine clearance <15ml/min)

10. Hypersensitivity against ivabradine or adjuvants

11. Pre-menopausal women